Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.


Journal

Carbohydrate research
ISSN: 1873-426X
Titre abrégé: Carbohydr Res
Pays: Netherlands
ID NLM: 0043535

Informations de publication

Date de publication:
15 Jan 2019
Historique:
received: 27 08 2018
revised: 26 10 2018
accepted: 28 10 2018
pubmed: 15 11 2018
medline: 5 6 2019
entrez: 15 11 2018
Statut: ppublish

Résumé

Galectins are a family of carbohydrate-recognizing proteins that by interacting with specific glycoepitopes can mediate important biological processes, including immune cell homeostasis and activation of tolerogenic circuits. Among the different members of this family, Galectin 1 and 3 have shown pro-tumorigenic effects, being overexpressed in numerous neoplasic diseases, proving to be relevant in tumor immune escape, tumor progression and resistance to drug-induced apoptosis. Thus, generation of specific glycosides that could inhibit their pro-tumorigenic ability by blocking their carbohydrate recognition domain is one of the current major challenges in the field. Considering that galectin-ligand binding strength is closely related to the ligand structure, analysis of this relationship provides valuable information for rational design of high-affinity ligands that could work as effective galectin inhibitors. Taking profit of the ability of glycosidases to catalyze transglycosylation reactions we achieved the enzymatic synthesis of β-d-Galp-(1 → 6)-β-d-Galp-(1 → 4)-d-Glcp(2), a mixture of β-d-Galp-(1 → 6)-β-d-Glcp-(1 → 4)-d-Glcp(5) and β-d-Galp-(1 → 3)-β-d-Glcp-(1 → 4)-d-Glcp(6), and finally benzyl β-d-galactopyranoside (9), with reaction yields between 16 and 27%. All the galactosides were purified, and characterized using

Identifiants

pubmed: 30428394
pii: S0008-6215(18)30495-6
doi: 10.1016/j.carres.2018.10.011
pii:
doi:

Substances chimiques

Blood Proteins 0
Galactosides 0
Galectin 1 0
Galectin 3 0
Galectins 0
LGALS1 protein, human 0
LGALS3 protein, human 0
Trisaccharides 0
Glycoside Hydrolases EC 3.2.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-15

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Cecilia Porciúncula González (C)

Laboratorio de Bioquímica, Departamento de Biociencias, Facultad de Química, UdelaR, Gral. Flores, 2124, Montevideo, Uruguay; Computational Chemistry and Biology Group, DETEMA, Facultad de Química, UdelaR, Isidoro de María 1614, 11800, Montevideo, Uruguay. Electronic address: dcpg@fq.edu.uy.

Alejandro J Cagnoni (AJ)

Laboratorio de Glicómica Funcional y Molecular, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), C1428ADN, Buenos Aires, Argentina. Electronic address: alejandrojcagnoni@gmail.com.

Karina V Mariño (KV)

Laboratorio de Glicómica Funcional y Molecular, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), C1428ADN, Buenos Aires, Argentina. Electronic address: kvmarinosp@gmail.com.

Carolina Fontana (C)

Laboratorio de Espectroscopía y Fisicoquímica Orgánica, Departamento de Química del Litoral, Facultad de Química & CENUR Litoral Norte, UdelaR. Ruta 3 km 363, 60000, Paysandú, Uruguay. Electronic address: cfontan@fq.edu.uy.

Patricia Saenz-Méndez (P)

Computational Chemistry and Biology Group, DETEMA, Facultad de Química, UdelaR, Isidoro de María 1614, 11800, Montevideo, Uruguay. Electronic address: psaenz@fq.edu.uy.

Gabriela Irazoqui (G)

Laboratorio de Bioquímica, Departamento de Biociencias, Facultad de Química, UdelaR, Gral. Flores, 2124, Montevideo, Uruguay. Electronic address: mgidrv@fq.edu.uy.

Cecilia Giacomini (C)

Laboratorio de Bioquímica, Departamento de Biociencias, Facultad de Química, UdelaR, Gral. Flores, 2124, Montevideo, Uruguay. Electronic address: cgiacomi@fq.edu.uy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH